Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.003 per share
-
Shares outstanding
-
792,553,191
-
Total 13F shares
-
61,433,344
-
Share change
-
-8,755,056
-
Total reported value
-
$46,074,279
-
Put/Call ratio
-
95%
-
Price per share
-
$0.75
-
Number of holders
-
57
-
Value change
-
-$7,738,535
-
Number of buys
-
19
-
Number of sells
-
20
Institutional Holders of Mereo BioPharma Group plc - Ordinary Shares, par value GBP 0.003 per share (MREO) as of Q4 2022
As of 31 Dec 2022,
Mereo BioPharma Group plc - Ordinary Shares, par value GBP 0.003 per share (MREO) was held by
57 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
61,433,344 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Rubric Capital Management LP, SUVRETTA CAPITAL MANAGEMENT, LLC, Rock Springs Capital Management LP, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC, Boxer Capital, LLC, Tejara Capital Ltd, ALKEON CAPITAL MANAGEMENT LLC, and Clearline Capital LP.
This page lists
57
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.